Car-t receipt&prepj admn
Use 38227 for receipt and preparation of the CAR T-cell product; use 38228 for administering it to the patient.
CMS RVU26D · Effective 2026-10-01
Report this service for administering a patient’s own genetically modified T cells as CAR T-cell therapy, rather than for collecting or preparing the cells. Compare 38228 office and facility rates across CMS payment localities in Maine.
Amounts below use the non-QP conversion factor for participating physicians. These are base physician payments before claim-level adjustments, not patient costs or total hospital charges.
Maine has 2 payment localities in this comparison. Use the service location to choose the applicable amount. These are the supported base rates for the 2 payment areas shown below, using the same CMS release.
$299.49–$314.60
2 of 2 localities have a supported rate.
$144.00–$147.12
2 of 2 localities have a supported rate.
These are locality ranges, not averages or address-specific quotes. A facility-setting amount covers the physician service; it does not include a hospital’s separate bill. Choose a locality below to inspect its calculation, compare other payment areas, or price a percentage of Medicare.
Cell therapy
Report this service for administering a patient’s own genetically modified T cells as CAR T-cell therapy, rather than for collecting or preparing the cells.
This code identifies the administration step of autologous chimeric antigen receptor (CAR) T-cell therapy. A patient’s T lymphocytes are collected and modified for treatment, then the resulting cell product is administered back to that patient. Hematologists, oncologists, and other clinicians involved in cellular therapy typically oversee the infusion in a hospital or specialized treatment setting. The code is specific to CAR T-cell administration, not conventional chemotherapy or hematopoietic stem-cell transplantation.
Select the code for the actual administration of the autologous CAR T-cell product. Collection and preparation activities occur at different stages and are represented by separate codes in the CAR T sequence when applicable. Documentation should identify the autologous CAR T product and record that it was administered, including the date and supporting infusion documentation. CMS assigns physician work, practice expense, and malpractice relative values to the service; no additional payment rule is listed in the supplied CMS facts.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Office rates for Maine, from the same CMS release.
Car-t receipt&prepj admn
Use 38227 for receipt and preparation of the CAR T-cell product; use 38228 for administering it to the patient.
Car-t prep t lymphcyt f/trns
38226 concerns preparing blood-derived T lymphocytes for transport. 38228 concerns administering the completed autologous CAR T-cell product.
Transplt autol hct/donor
38241 describes autologous hematopoietic cell transplantation. 38228 is specific to administration of autologous CAR T cells.
Find the payment area for your service address, then open its rate page for calculation inputs, release history and the percentage-of-Medicare tool. A city may cross payment-area boundaries; the ZIP lookup above helps resolve the location.
2 of 2 payment localities
Office / nonfacility
$299.49
Facility
$144.00
Office / nonfacility
$314.60
Facility
$147.12
Fee-sheet and API access are in early access. Tell us which codes and locations your team needs.
38228 identifies administration of the autologous CAR T-cell product. 38227 describes receipt and preparation of the product for administration, a distinct step.
No. It represents administration, not collection of the patient’s T cells or preparation of cells for transport or infusion.
Document that the product was autologous CAR T cells and that administration occurred. The infusion record should support the date and service performed.
No. Collection is a separate service; 38228 is selected for the later administration of the CAR T-cell product.
FeeBase calculates base physician payments from CMS work, practice-expense, and malpractice RVUs, adjusted by each locality’s geographic indices and the applicable conversion factor. Unavailable or separately priced services are labeled rather than assigned a made-up amount.
Source: RVU26D. Effective 2026-10-01 through the day before 2027-01-01.